Welcome to the e-CCO Library!

DOP41: Mucosal single-cell profiling of Crohn's-like disease of the pouch reveal unique pathogenesis and therapeutic targets
Year: 2024
Source: ECCO'24 Stockholm
Authors: Deepak, Parakkal
Created: Tuesday, 30 April 2024, 5:03 PM
DOP41: Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study
Year: 2021
Source: ECCO'21 Virtual
Authors: Quaresma, A.B.(1);Damiao, A.O.M.C.(2);Coy, C.S.R.(3);Magro, D.O.(3);Valverde, D.A.(4);Panaccione, R.(5);Coward, S.B.(6);Ng, S.C.(7);Kaplan, G.G.(6);Kotze, P.G.(8)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Bohn Thomsen1, R. Ungaro2, K. Allin3, G. Poulsen1, A. Mikael1, J.F. Colombel2, T. Jess1

Created: Thursday, 30 January 2020, 10:12 AM
DOP42: Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Sigall Boneh*1,2, J. Van Limbergen3, A. Assa4, R. Shaoul5, E. Wine6, P. Milman7, S. Cohen8, M. Kori9, S. Peleg10, A. On11, H. Shamaly12, L. Abramas1, A. Levine1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP42: Dietary Therapies Induce Rapid Response and Remission in Active Paediatric Crohn’s Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Rotem Sigall-Boneh
Created: Tuesday, 28 May 2019, 3:32 PM
CRP and other serum biomarkers, Disease activity Indices, Dietary therapy, Exclusive enteral nutrition, Paediatric, Disease activity indices
Files: 1
DOP42: Disease course and clinical outcomes in Taiwan Crohn’s Disease patients with perianal fistula: A nationwide-based study
Year: 2021
Source: ECCO'21 Virtual
Authors: Weng, M.T.(1);Lin, K.L.(2);Chan, K.A.(3);Wei, S.C.(4)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP42: Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study
Year: 2022
Source: ECCO'22
Authors: Danese, S.(1);Panaccione, R.(2);D'Haens, G.(3);Peyrin-Biroulet, L.(4);Schreiber, S.(5);Kobayashi, T.(6);Gawdis-Wojnarska, B.(7);Korga, P.(8);Aguilar, H.(9);Sharkey, B.(10);Sreih, A.(11);Radosti, C.(10);Patel, A.(10);Canavan, J.(10);Rubin, D.(12);
Created: Friday, 11 February 2022, 3:52 PM
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chaparro, M.(1)*;Armuzzi, A.(2);Irving, P.M.(3,4);Allez, M.(5);Dubinsky, M.C.(6);Sands, B.E.(7);Goetsch, M.(8);Wang, W.(9);Shan, K.(10);Woolcott, J.(11);Bartolome, L.(12);Wosik, K.(13);Panaccione, R.(14);
Created: Friday, 14 July 2023, 10:43 AM
DOP42: Impact of discontinuing thiopurines at anti-TNF initiation in Inflammatory Bowel Disease: A nationwide Danish cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Sandra Bohn Thomsen
Created: Tuesday, 23 June 2020, 5:40 PM
DOP42: Impact of discontinuing thiopurines at anti-TNF initiation in Inflammatory Bowel Disease: A nationwide Danish cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Sandra Bohn Thomsen
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP43 The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.Z.S. Lo, M. Zhao, I. Vind, J. Burisch

Created: Thursday, 30 January 2020, 10:12 AM
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Axel Dignass
Created: Friday, 14 July 2023, 2:22 PM
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dignass, A.(1)*;Regueiro, M.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Vermeire, S.(5);Rubin, D.T.(6);
Created: Friday, 14 July 2023, 10:43 AM
DOP43: Impact of Inflammatory Bowel Diseases on the phenotype and severity of psoriasis and spondyloarthropathies
Year: 2021
Source: ECCO'21 Virtual
Authors: Attauabi, M.(1,2,3);Damsgaard Wewer, M.(1,3);Bendtsen, F.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: Results of the OCTAVE Open study for tofacitinib delayed responders
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Milan Lukas
Created: Tuesday, 28 May 2019, 3:32 PM
Tofacitinib
Files: 1
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. T. Rubin1, M. C. Dubinsky2, M. Lukas*3, D. Quirk4, C. I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, H. Fan4, D. A. Woodworth4, G. Chan4, C. Su4

Created: Friday, 22 February 2019, 9:41 AM
DOP43: Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North
Year: 2022
Source: ECCO'22
Authors: Siegmund, B.(1);Axelrad, J.(2);Pondel, M.(3);Osterman, M.T.(3);Ahmad, H.A.(3);Memaj, A.(3);Regueiro, M.(4);Armuzzi, A.(5);Afzali, A.(6);
Created: Friday, 11 February 2022, 3:52 PM